tirzepatide ruling 2025 Associated with Lower POAG, OHT Risk Compared with Other GLP-1 Drugs The Impact of New FDA

How is tirzepatide different from semaglutide mechanistically

3941 Semaglutide and tirzepatide seem to uniquely modulate GABA release in the central amygdala and infralimbic cortex

At ESC Congress 2025, conflicting evidence emerged: a post hoc analysis suggested tirzepatide could offer greater long-term cardiovascular risk reduction, while the STEER real-world study favored semaglutide for major adverse cardiovascular events

Visceral fat measurements show meaningful reduction

Water is necessary for lipolysis, which is the process the body uses to break down fat for energy

This means that food - and alcohol stay in the stomach longer